Zurich · Swiss & DACH desk
Precision capital for precision science.
Switzerland holds an unusual concentration of pharma decision-makers and patient private capital. We use both: partnering routes for portfolio companies, and long-horizon LP relationships.
Focus
Pharma partnering · LPs
Cheque
US$10M+
Markets
CH · DE · AT
Time zone
CET/CEST
Partnering and licensing
Basel and Zurich pharma relationships give portfolio companies a realistic read on what a partnered programme is worth before they price a round on it.
Private and institutional capital
Swiss and German family offices and private banks access Fund III, co-invest and SPV structures with reporting matched to their governance requirements.
Frequently asked questions
- Do you invest directly in Swiss biotech?
- Selectively, generally co-investing with a domestic lead where we add manufacturing or Asian market access.
- Can DACH family offices invest in Fund III?
- Yes, subject to eligibility and standard onboarding checks.
- Do you help with pharma introductions?
- Yes — structured partnering introductions are part of our value-add, not a favour.